MLYS insider reports sale of 6,348 shares

Mineralys Therapeutics (MLYS) reported insider dispositions.

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) reported insider dispositions. David Rodman reported multiple sales of Common Stock over January–March 2026, including a broker-assisted cashless exercise reported on 03/12/2026 covering 6,348 shares. The filing lists several prior dispositions in the three months before that date with individual sale dates and share counts.

Insights

Corporate Governance Analyst

Routine insider dispositions reported; timing and amounts are disclosed.

The filing lists a broker-assisted cashless exercise of 6,348 shares on 03/12/2026 and multiple prior sales in January–March 2026. These entries document transactions by a reporting person rather than corporate action.

Cash-flow treatment and any use of proceeds are not detailed in the excerpt; subsequent SEC filings would show further position context or plan disclosures.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) disclose in this Form 144?

The filing discloses reported dispositions of Common Stock by David Rodman, including a 6,348-share broker-assisted cashless exercise on 03/12/2026. It lists multiple prior sales with dates and share counts in January–March 2026.

How many shares were reported sold on 03/12/2026 in the MLYS Form 144?

The Form 144 lists a broker-assisted cashless exercise of 6,348 shares on 03/12/2026. The entry is shown under "Securities To Be Sold" with that exact share count and date.

Who is the reporting person that sold MLYS shares in the filing?

The reporting person named in the excerpt is David Rodman. Multiple sale entries in January–March 2026 are attributed to that individual with specific share counts and dollar amounts per transaction.

Does the Form 144 state how proceeds will be used?

The provided excerpt does not state any use-of-proceeds information. The entries list transaction types, dates, share counts, and dollar amounts but do not specify how proceeds were applied.

Are the prior sales in the past three months detailed in the filing?

Yes; the filing lists several prior dispositions by date with share counts and dollar amounts across January–March 2026, including transactions of 192,715, 70,037, and other share amounts shown alongside transaction dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001672659
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Rodman David Malcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	6348	173748.15	79139956	03/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	03/12/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6348	03/12/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/12/2026	6349	184076.52
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/16/2026	14055	385732.29
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/17/2026	417	11505.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/09/2026	2171	58269.64

144: Remarks and Signature

Remarks
Date of Notice	03/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	David Rodman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)